Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 4/20 | 0.64 |
| ▸ | GFER | P55789 | 1/20 | 0.59 |
| ▸ | CA2 | P00918 | 3/20 | 0.57 |
| ▸ | MAOA | P21397 | 2/20 | 0.50 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.48 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.44 |
| ▸ | HTR2A | P28223 | 1/20 | 0.43 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.43 |
| ▸ | RECQL | P46063 | 1/20 | 0.42 |
| ▸ | LTB4R | Q15722 | 1/20 | 0.42 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9806863 | 0.98 | MAOB (0.61) | MAOBGFERCA2MAOACYP4F2 | |
| SCHEMBL1452380 | 0.98 | MAOB (0.61) | MAOBGFERCA2MAOACYP4F2 | |
| SCHEMBL2380716 | 0.98 | MAOB (0.61) | MAOBGFERCA2MAOACYP4F2 | |
| SCHEMBL10357817 | 0.98 | MAOB (0.61) | MAOBGFERCA2MAOACYP4F2 | |
| SCHEMBL4300050 | 0.98 | MAOB (0.61) | MAOBGFERCA2MAOACYP4F2 | |
| SCHEMBL979851 | 0.93 | GFER (0.62) | MAOBGFERCA2MAOACYP4A11 | |
| SCHEMBL3111509 | 0.87 | MAOB (0.80) | MAOBGFERMAOAALDH1A1CYP3A4 | |
| SCHEMBL242504 | 0.87 | CA2 (0.61) | MAOBCA2CYP4F2CYP4A11ALDH1A1 | |
| SCHEMBL7140170 | 0.86 | GFER (0.54) | MAOBGFERCA2MAOACYP4A11 | |
| SCHEMBL10451946 | 0.86 | HTR2A (0.59) | CA2MAOACYP4F2CYP4A11ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 93 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9920343-B2 | Method for producing aniline derivative by fermentation from carbon source | JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) | 2018-03-20 | — | — | US | claimed |
| US-20170022528-A1 | METHOD FOR PRODUCING ANILINE DERIVATIVE BY FERMENTATION FROM CARBON SOURCE | JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) | 2017-01-26 | — | — | US | claimed |
| EP-3121275-A1 | METHOD FOR PRODUCING ANILINE DERIVATIVE BY FERMENTATION FROM CARBON SOURCE | Japan Science and Technology Agency (JP) | 2017-01-25 | — | — | EP | claimed |
| US-12286426-B2 | Heterocyclic mitochondrial activity inhibitors and uses thereof | Université de Montréal (CA) | 2025-04-29 | — | — | US | disclosed |
| EP-3704111-B1 | HETEROCYCLIC MITOCHONDRIAL ACTIVITY INHIBITORS AND USES THEREOF | UNIV MONTREAL (CA) | 2024-10-09 | — | — | EP | disclosed |
| US-12065421-B2 | Inhibitors of oplophorus luciferase-derived bioluminescent complexes | PROMEGA CORPORATION (US) | 2024-08-20 | — | — | US | disclosed |
| EP-4140991-B1 | INHIBITORS OF OPLOPHORUS LUCIFERASE-DERIVED BIOLUMINESCENT COMPLEXES | PROMEGA CORP (US) | 2024-05-15 | — | — | EP | disclosed |
| CN-111886234-B | Heterocyclic mitochondrial activity inhibitors and uses thereof | 蒙特利尔大学 | 2023-12-15 | — | — | CN | disclosed |
| US-20230357221-A1 | HETEROCYCLIC MITOCHONDRIAL ACTIVITY INHIBITORS AND USES THEREOF | UNIV MONTREAL (CA) | 2023-11-09 | — | — | US | disclosed |
| US-20230357221-A1 | HETEROCYCLIC MITOCHONDRIAL ACTIVITY INHIBITORS AND USES THEREOF | UNIV MONTREAL (CA) | 2023-11-09 | — | — | US | disclosed |
| US-20230357221-A1 | HETEROCYCLIC MITOCHONDRIAL ACTIVITY INHIBITORS AND USES THEREOF | UNIV MONTREAL (CA) | 2023-11-09 | — | — | US | disclosed |
| EP-0131302-B1 | IMIDAZOLIUM SALTS, INTERMEDIATES THERETO AND THEIR USE | SCHERING AKTIENGESELLSCHAFT (DE) | 1992-01-29 | — | — | EP | disclosed |
| US-4853382-A | TREATING ASTHMA AND BRONCHITIS | GLAXO GROUP LIMITED (GB) | 1989-08-01 | — | — | US | disclosed |
| EP-0178919-B1 | AMINOPHENOL DERIVATIVES | GLAXO GROUP LIMITED (GB) | 1988-12-21 | — | — | EP | disclosed |
| US-4730008-A | STIMULANT FOR BETA-ADRENORECEPTORS | GLAXO GROUP LIMITED (GB) | 1988-03-08 | — | — | US | disclosed |
| CN-86102681-A | The preparation method of p-aminophenol derivative and purposes | — | 1987-10-28 | — | — | CN | disclosed |
| US-4689341-A | Antiarrhythmic imidazoles | SCHERING A.G. (DE) | 1987-08-25 | — | — | US | disclosed |
| US-4613609-A | Antiarrhythmic imidazoliums | SCHERING A. G. (DE) | 1986-09-23 | — | — | US | disclosed |
| US-4581370-A | Antiarrhythmic imidazoliums | SCHERING A.G. (DE) | 1986-04-08 | — | — | US | disclosed |
| EP-0131302-A2 | Imidazolium salts, intermediates thereto and their use | SCHERING AKTIENGESELLSCHAFT (DE) | 1985-01-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230357221-A1 | HETEROCYCLIC MITOCHONDRIAL ACTIVITY INHIBITORS AND USES THEREOF | IDH2, TFAM, IDH1 | MAOB 3874/4885GFER 4248/4885CA2 425/4885 |
| US-12065421-B2 | Inhibitors of oplophorus luciferase-derived bioluminescent complexes | LUC7L2, LYPLAL1, GUSB | MAOB 2567/4885GFER 3510/4885CA2 3483/4885 |
| US-12286426-B2 | Heterocyclic mitochondrial activity inhibitors and uses thereof | IDH2, TFAM, IDH1 | MAOB 3874/4885GFER 4248/4885CA2 425/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.